Company: REVB
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000950170-25-105284
Chunk: 4

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 2
Chunk 4
---
  Loss from operations                                           (2,461,229      (2,522,397         61,168      (4,556,216       (4,424,535       (131,681  
  Total other income (expense), net                                  16,847      (5,867,422      5,884,269          60,749       (6,646,717      6,707,466  
  Net loss                               $                       (2,444,382      (8,389,819      5,945,437      (4,495,467      (11,071,252      6,575,785  

Research and Development Expenses

The following table summarizes our research and development expenses for the periods presented:

                                                               Three Months Ended                                                                                         
                                                               June 30,                                                                                                   
                                                               2025                                                                                                       
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  GEM-AKI, GEM-CKD and GEM-PSI clinical study expenses         $                         961,428        967,577       (6,149      1,432,005      1,300,802       131,203  
  Other expenses                                                                          20,570        112,180      (91,610         44,183        201,195      (157,012  
  Personnel expenses (including stock-based compensation)                                335,982        315,172       20,810        700,622        610,514        90,108  
  Total research and development expenses                      $                       1,317,980      1,394,929      (76,949      2,176,810      2,112,511        64,299  

Research and development expenses decreased by $0.1 million, from $1.4 million for the three months ended June 30, 2024 to $1.3 million for the three months ended June 30, 2025. The decrease was primarily due to a decrease of other research and development expenses.

Research and development expenses increased by $0.1 million, from $2.1 million for the six months ended June 30, 2024 to $2.2 million for the six months ended June 30, 2025. The increase was primarily due to increases of $0.1 million of clinical study expense and